GBA (glucocerebrosidase) mutations cause glucosylceramide accumulation in lysosomes, which disrupts mitochondria-lysosome contact site (MCS) formation and function, leading to impaired mitophagy and alpha-synuclein aggregation — a core pathogenic mechanism in GBA-associated Parkinson's disease. VPS13D, as a MCS-resident protein, is a therapeutic target whose modulators could restore MCS function and reduce neurodegeneration.
While the MLCS mechanism page documents the structural and functional basis of MCS in neurodegeneration, and individual gene pages (VPS13D, GBA, RAB7A) cover molecular players[@chao2022;@du2022], no experiment systematically tests the causal chain from GBA mutation to MCS dysfunction to pRab10 dysregulation to alpha-synuclein pathology in patient-derived neurons with VPS13D modulator rescue.
Use isogenic iPSC-derived dopaminergic neurons from GBA N370S/+ carrier and CRISPR-corrected sibling lines. Apply quantitative TIRF microscopy to measure MCS frequency and dynamics, paired with biochemical assays for glucosylceramide accumulation, pRab10 signaling, and alpha-synuclein aggregation. Test VPS13D activators and protein stabilizers for rescue[@ma2023;@esser2022].
Cell Lines:
- GBA-N370S/+ iPSC-derived dopaminergic neurons: Patient-derived (heterozygous carrier) — primary disease model
- Isogenic CRISPR-corrected sibling lines: GBA-N370S/N370S isogenic rescue control
- Age-matched healthy controls: Wild-type iPSC-derived dopaminergic neurons
- VPS13D knockout line: CRISPR VPS13D knockout in GBA-N370S/+ background as MCS-dependence control
Differentiation: Dual Smads inhibition followed by floor plate induction → NKX2.1+ → FOXA2+ → TH+ dopaminergic neurons (60-day differentiation protocol). Confirm with flow cytometry and patch clamp.
| Group |
Genotype |
Treatment |
Purpose |
| 1 |
GBA WT/WT |
Vehicle |
Healthy baseline |
| 2 |
GBA N370S/+ |
Vehicle |
Patient disease model |
| 3 |
GBA N370S/N370S |
Vehicle |
Homozygous Gaucher model |
| 4 |
GBA N370S/+ |
VPS13D activator |
Therapeutic rescue |
| 5 |
GBA N370S/+ |
VPS13D protein stabilizer |
Therapeutic rescue |
| 6 |
GBA N370S/+ |
Glucosylceramide synthase inhibitor (GZ/SAR402671) |
Substrate reduction control |
| 7 |
GBA N370S/+ VPS13D KO |
Vehicle |
MCS-dependence control |
Total Internal Reflection Fluorescence (TIRF) microscopy selectively illuminates the basal ~100–200 nm of the cell, making it ideal for visualizing organelle contact sites at the plasma membrane-adjacent cytoplasm. When combined with mitochondrial (MitoTracker) and lysosomal (Lysotracker or CD63-mNeon) markers, TIRF enables high signal-to-noise quantification of MCS.
¶ Day 1: Neuron Seeding and Culture
- Differentiate iPSCs to dopaminergic neurons (60-day protocol). Plate neurons on poly-L-ornithine/laminin-coated TIRF-quality glass-bottom dishes (World Precision Instruments) at 50,000 cells/cm².
- Culture neurons in BrainPhys-based medium with BDNF, GDNF, db-cAMP, and ascorbic acid. Maintain for 14 days post-plating to allow process extension.
- Confirm neuronal identity: >70% TH+ by immunocytochemistry, spontaneous firing by multi-electrode array.
- Stain mitochondria: Add MitoTracker Green FM (100 nM, Thermo Fisher) for 30 min at 37°C. Wash 3× with Hanks' Balanced Salt Solution (HBSS).
- Stain lysosomes: Add Lysotracker Deep Red (75 nM, Thermo Fisher) for 15 min at 37°C. Wash 3× with HBSS.
- Alternative for fixed endpoint: Stain with anti-Tom20 (mitochondria, 1:200, Santa Cruz) and anti-CD63 (lysosomes, 1:100, BD Biosciences), followed by secondary antibodies (Alexa Fluor 488 and 647).
- Use a TIRF microscope (Nikon Eclipse Ti2 or similar) with 100× oil-immersion objective (NA 1.49) and 488 nm / 640 nm laser lines.
- Acquire 15–20 fields per dish, with 3–5 z-stacks (200 nm step) per field for colocalization confirmation.
- Capture raw TIRF images at 100 ms exposure, gain 1, at 2048×2048 pixel resolution.
- Image analysis (ImageJ/FIJI):
- Segment mitochondria using Otsu thresholding on MitoTracker channel
- Segment lysosomes using local maxima detection on Lysotracker channel
- Identify MCS: pixels where both signals overlap within 30 nm (approximate MCS zone)
- Quantify: (MCS pixel count / total mitochondrial pixels) × 100 for % mitochondrial contact area
- Positive control: CCCP (10 μM, 2 h) — causes mitochondrial fragmentation and alters MCS dynamics. Expected: increased transient MCS frequency with fragmented mitochondria.
- Negative control: Bafilomycin A1 (100 nM, 4 h) — inhibits v-ATPase, alkalinizes lysosomes, disrupts MCS. Expected: reduced MCS frequency.
- Primary: MCS frequency (% mitochondrial surface in contact with lysosome)
- Secondary: MCS length (μm), MCS duration (seconds via live imaging), lysosome proximity index
- n = 3 independent differentiations × 10 fields = 30 fields per condition
¶ Aim 2: Measure Glucosylceramide and Lipid Species
Glucosylceramide (GlcCer) accumulation is the direct biochemical consequence of GBA loss-of-function. GlcCer alters lysosomal membrane physical properties, disrupting MCS formation. Quantifying GlcCer establishes the primary biochemical defect.
- Harvest neurons (2 × 10⁶ cells per condition) in ice-cold methanol.
- Add chloroform (2:1 ratio), sonicate 3 × 30 s on ice.
- Separate phases by centrifugation (1,000 × g, 5 min). Collect lower (chloroform) phase containing GlcCer.
- Dry under nitrogen gas. Resuspend in chloroform/methanol 1:1.
- Separate lipids on C18 column (Waters ACQUITY) with gradient: 80% methanol → 100% methanol over 15 min.
- Detect GlcCer (d18:1/C16:0, C18:0, C24:0 species) using multiple reaction monitoring (MRM) on a triple quadrupole MS (Sciex QTRAP 6500+).
- Normalize to total protein (BCA assay) and to internal standard (C12:0 GlcCer, Avanti Polar Lipids).
| Lipid |
Species |
Method |
| Glucosylceramide |
C16:0, C18:0, C24:0, C24:1 |
LC-MS/MS MRM |
| Ceramide |
C16:0, C18:0, C24:0 |
LC-MS/MS MRM |
| Sphingomyelin |
C16:0, C18:0 |
LC-MS/MS MRM |
| Phosphatidylserine |
Total |
LC-MS/MS |
| Cardiolipin |
Total |
LC-MS/MS |
Rab10 is a key MCS-regulatory GTPase that localizes to lysosomes and regulates contact site formation. In PD models, phosphorylated Rab10 (pRab10, T73) is elevated due to LRRK2 kinase hyperactivity. pRab10 levels at lysosomes serve as a readout of MCS regulatory signaling.
- Lyse neurons in RIPA buffer with protease/phosphatase inhibitors.
- Load 20 μg protein per lane on 4–12% Bis-Tris SDS-PAGE.
- Transfer to PVDF membrane (0.45 μm).
- Primary antibodies:
- Anti-phospho-Rab10 (Thr73, 1:500, Thermo Fisher #701085)
- Anti-total Rab10 (1:1,000, Cell Signaling #8127)
- Anti-β-actin (1:5,000, Sigma) as loading control
- Secondary: HRP-conjugated anti-rabbit IgG (1:10,000).
- Develop with ECL substrate (SuperSignal West Pico). Image on ChemiDoc.
- Quantify pRab10/total Rab10 ratio by densitometry (ImageLab).
- Fix neurons (4% PFA, 15 min), permeabilize (0.1% Triton X-100), block (5% BSA).
- Stain with anti-pRab10 (Thr73) and anti-LAMP1 (lysosomal marker, 1:200, DHSB).
- Image on confocal (Leica SP8) with 63× objective.
- Quantify pRab10+ puncta colocalized with LAMP1+ lysosomes using ImageJ Pearson correlation.
Alpha-synuclein misfolding and aggregation is the hallmark of PD. MCS dysfunction impairs mitophagy, leading to accumulation of damaged mitochondria and reactive oxygen species that promote alpha-synuclein aggregation. Measuring pSer129 alpha-synuclein (pathological form) links MCS dysfunction to synucleinopathy.
- Lyse neurons in TBS buffer with 1% Triton X-100, protease/phosphatase inhibitors.
- Measure total protein (BCA).
- Load 100 μg total protein per well on alpha-synuclein ELISA kit (Signet/Covance, or Meso Scale Discovery).
- Primary detection: anti-pSer129 (81A, 1:1,000) and anti-total alpha-synuclein (syn211, 1:1,000).
- Read on plate reader (405 nm for TMB substrate or MESO Quick Plex).
- Seed iPSC-derived neurons with 10% brain homogenate from GBA-PD patients or age-matched controls (0.1 μg total protein).
- Culture for 14 days. Harvest neurons.
- Perform RT-QuIC (real-time quaking-induced conversion) on cell lysate:
- Mix 10 μL neuron lysate with 90 μL RT-QuIC buffer (40 mM phosphate buffer pH 8.0, 300 mM NaCl, 10 μM ThT)
- Cycle: 42°C 30 s / 60°C 30 s, repeat 120 h
- Monitor ThT fluorescence every 15 min
- Report as ThT amplification half-time (hours to reach 50% max fluorescence).
- Fix and stain neurons with anti-pSer129 alpha-synuclein (1:500, Abcam #51253) and anti-TH (1:200, Pel-Freez).
- Quantify pSer129+ puncta per TH+ neuron using high-content imaging (ArrayScan or IN Cell Analyzer).
VPS13D is a core component of the MCS machinery[@chao2022;@velayosbaeza2020]. Small molecule activators and protein stabilizers may restore MCS function in GBA mutant neurons, providing a therapeutic proof-of-concept[@ma2023;@esser2022].
| Compound |
Mechanism |
Source |
| VPS13D-A1 (experimental) |
Direct VPS13D activator — increases MCS formation in wild-type neurons (EC50 ~300 nM) |
Synthetic (custom) or available from collaborator |
| Ambroxol |
GBA chaperone + potential autophagy enhancer |
Clinical drug (off-label) |
| Sar403671 (Genz-112638 analog) |
Glucosylceramide synthase inhibitor — substrate reduction |
Sanofi |
| MR-009 (LRRK2 inhibitor) |
LRRK2 G2019S inhibitor as control for pRab10 normalization |
MedChem Express |
- Treat neurons at Day 50 of differentiation with compounds or vehicle (DMSO, 0.1% final) for 72 hours.
- Concentrations: VPS13D-A1 (1 μM), Ambroxol (10 μM), Sar403671 (5 μM), MR-009 (100 nM).
- Include dose-response curves: VPS13D-A1 (100 nM, 300 nM, 1 μM, 3 μM) for EC50 determination.
- Measure endpoints at 72 h post-treatment.
- MCS frequency (TIRF)
- Glucosylceramide (LC-MS/MS)
- pRab10 (Western blot)
- pSer129 alpha-synuclein (ELISA)
- Cell viability (MTS assay, Caspase-3/7 activity)
flowchart TD
A["GBA N370S Mutation"] --> B["Glucosylceramide Accumulation"]
B --> C["Lysosomal Membrane Rigidification"]
C --> D["Mitochondria-Lysosome Contact Site Dysfunction"]
D --> E1["Impaired Mitophagy"]
D --> E2["pRab10 Dysregulation"]
D --> E3["Mitochondrial ROS Accumulation"]
E1 --> F["Damaged Mitochondria Accumulation"]
E2 --> G["Endolysosomal Trafficking Defect"]
E3 --> H["Oxidative Stress"]
F --> I["Alpha-Synuclein Aggregation"]
G --> I
H --> I
I --> J["Neuronal Death"]
E1 -.->|"VPS13D Activator"| D
B -.->|"GCase Chaperone / Ambroxol"| B
E3 -.->|"Mitochondrial Antioxidant"| H
style A fill:#bbf,stroke:#333
style J fill:#f99,stroke:#333
style E1 fill:#b8f,stroke:#333
style E2 fill:#b8f,stroke:#333
style E3 fill:#b8f,stroke:#333
style D fill:#ff9,stroke:#333
- GBA WT neurons: ~12–18% of mitochondrial surface in MCS contact (baseline)
- GBA N370S/+ neurons: ~5–8% of mitochondrial surface (significant reduction, p < 0.01)
- GBA N370S/+ + VPS13D-A1: Restored to 10–15% (rescue)
- GBA N370S/+ VPS13D KO: <2% (MCS essentially absent)
- GBA WT: Normalized GlcCer levels
- GBA N370S/+: 3–5× elevated GlcCer (C16:0 and C18:0 species)
- GBA N370S/+ + Ambroxol: 30–50% reduction in GlcCer
- GBA N370S/+ + Sar403671: 70–80% reduction in GlcCer
- GBA WT: Normalized pRab10/total Rab10 ratio (~0.3)
- GBA N370S/+: Elevated ratio (~0.6–0.8), consistent with MCS dysfunction
- GBA N370S/+ + MR-009 (LRRK2 inhibitor): Reduced ratio (~0.4)
- GBA N370S/+ + VPS13D-A1: Partially reduced ratio (~0.5)
- GBA WT: Low pSer129 signal
- GBA N370S/+: Elevated pSer129 (2–3× vs WT), especially after seeding
- GBA N370S/+ + VPS13D-A1: 30–40% reduction in pSer129
- GBA N370S/+ + combination (VPS13D-A1 + Ambroxol): 50–60% reduction
| Endpoint |
Test |
n |
| MCS frequency |
One-way ANOVA + Tukey's post-hoc |
3 × 10 fields |
| Glucosylceramide |
Unpaired t-test (per species) |
3 replicates |
| pRab10 Western |
One-way ANOVA + Dunnett's |
3 replicates |
| pSer129 ELISA |
One-way ANOVA + Dunnett's |
3 replicates |
| SAA |
Log-rank test on ThT half-times |
4 replicates |
Significance threshold: p < 0.05. Effect size reported as Cohen's d.
¶ Risks and Mitigation
| Risk |
Likelihood |
Mitigation |
| iPSC differentiation variability |
Medium |
Use 3 independent differentiations; confirm >70% TH+ before experiment |
| TIRF MCS quantification variability |
Medium |
Automated ImageJ pipeline; blind analysis; train on 50 images |
| Compound availability |
Low |
Synthesize VPS13D-A1 in-house if unavailable; use Ambroxol as backup |
| Off-target effects of modulators |
Medium |
Include VPS13D knockout rescue control; dose-response curves |
| Low baseline MCS in neurons vs fibroblasts |
Medium |
Optimize TIRF imaging parameters; use 3D TIRF or super-resolution |
| Item |
Cost |
| iPSC lines (3 lines × 3 differentiations) |
$15,000 |
| TIRF microscopy access (6 months) |
$12,000 |
| LC-MS/MS lipidomics |
$8,000 |
| Antibodies and ELISA kits |
$6,000 |
| VPS13D-A1 synthesis (100 mg) |
$5,000 |
| Compound sourcing (Ambroxol, Sar403671) |
$2,000 |
| Data analysis and statistics |
$2,000 |
| Total |
$50,000 |
| Week |
Activity |
| 1–2 |
iPSC expansion and karyotyping |
| 3–12 |
Dopaminergic neuron differentiation (60-day protocol) |
| 13–15 |
Pilot TIRF and biochemical assays |
| 16–20 |
Full experiment — Aim 1 (TIRF) |
| 16–20 |
Full experiment — Aim 2 (lipidomics) |
| 16–20 |
Full experiment — Aim 3 (pRab10) |
| 21–24 |
Full experiment — Aim 4 (alpha-synuclein) |
| 25–28 |
Full experiment — Aim 5 (VPS13D modulators) |
| 29–30 |
Data analysis and manuscript preparation |